This study was performed to assess the utility of tumor-derived fragmentary DNA, or
circulating tumor DNA (ctDNA), for identifying high-risk patients for relapse of acute myeloid …

Bone metastasis occurs frequently in cancer patients. Conventional therapies have limited
therapeutic outcomes, and thus, exploring the mechanisms of cancer progression in bone …

Genome research using appropriately collected pathological tissue samples is expected to
yield breakthroughs in the development of biomarkers and identification of therapeutic …

Original research: Clinical significance of plasma-free amino acids and tryptophan metabolites
in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for …

Myxofibrosarcoma (MFS) and undifferentiated sarcoma (US) have been considered as tumors
of the same lineage based on genetic/epigenetic profiling. Although MFS shows a notably …

The pancreatic cancer microenvironment is crucial in cancer development, progression and
drug resistance. Cancer-stromal interactions have been recognized as important targets for …

Lynch syndrome is a hereditary disease characterized by an increased risk of colorectal and
other cancers. Germline variants in the mismatch repair (MMR) genes are responsible for …

Patient-derived xenograft models reportedly represent original tumor morphology and gene
mutation profiles. In addition, patient-derived xenografts are expected to recapitulate the …

Background Interstitial pneumonia (IP) is a poor prognostic comorbidity in patients with non-small
cell lung cancer (NSCLC) and is also a risk factor for pneumonitis. The TORG1936/…

A growing body of evidence suggests that tumor-derived fragmentary DNA, known as circulating
tumor DNA (ctDNA), has the potential to serve as a non-invasive biomarker for disease …